The use of highly purified, virally attenuated, plasma-derived coagulation factor products, followed by recombinant factor IX concentrates, lowered the risk of severe bleeding and the transmission of infectious agents, so that the development of inhibitory antibodies is nowadays the most serious complication found in hemophilia B patients [2]. This evidence concerns the gene F9 and hemophilia B.